Full
Outline
Naoan Dropping Pills（Capsules）［脑安滴丸（胶囊）］is a type B medicine included in medical insurance in China，which is extracted from Chuanxiong（Chuanxiong Rhizoma），Danggui（Angelicae Sinensis Radix），Renshen（Ginseng Radix et Rhizoma），Honghua（Carthami Flos），Bingpian（Borneolum Syntheticum）and other raw materials，and has the effect of activating blood circulation and removing blood stasis，promoting Qi and opening collaterals. Since its introduction to the market nearly 20 years ago，Naoan Dropping Pills has been widely used in clinical practice，and can be used for hemiplegia，hemianopsia，dysarthria，dysarthria caused by cerebral thrombosis，as well as amnesia，dizziness，nausea，photophobia，and fatigue caused by migraine headache，which are symptoms of Qi deficiency and blood stasis，and so on. However，there is currently no guideline or consensus based on evidence to guide the clinical use of Naoan Dropping Pills（Capsules）. With the support of the Chinese Society of Traditional Chinese Medicine（CSTCM），Dongzhimen Hospital of Beijing University of Chinese Medicine（BUCM）led the 24 Chinese units to compile this consensus. The clinical issues to be addressed were identified through a nominal group approach，whereby the drug inserts were systematically reviewed and a clinical study was conducted involving 110 clinicians from across the country. According to the clinical questions，the evidence of clinical studies was systematically retrieved. The GRADE system was used to evaluate the quality of the evidence，and finally，the recommendation/consensus suggestion was reached through the nominal group method. The consensus provides a detailed specification of the medication characteristics，including the timing of medication intervention，dosage，duration of use，precautions，contraindications，and adverse reactions and treatments of Naoan Dropping Pills（Capsules）for the treatment of migraine. This will facilitate the standardisation of the clinical application of this product，improve the clinical efficacy and reduce the risk of medication. At present，this consensus has been reviewed and published by the Standardization Office of the China Association of Chinese Medicine，with a standard number of GS/CACM 359-2024.
100
15
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |
关闭全屏
No. 86 Xueyuan South Road, Haidian District, Beijing
010-62662699(Operation and Technical Support)
qkjq@cast.org.cn
Copyright © 2025 China Association for Science and Technology. All rights reserved. For all open access content, the relevant licensing terms apply.
Sponsored by the Office of the Leading Group for Cybersecurity and Informatization of CAST, and supported by Science and Technology Review Publishing House
